Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions

TUCSON, Ariz., June 24, 2021 — Critical Path Institute (C-Path) today announced it has named Scottie Kern, as both Executive Director of the Electronic Patient-Reported Outcome (ePRO) Consortium and Associate Director of the Patient-Reported Outcome (PRO) Consortium and Terina N. Martínez, Ph.D., as Executive Director of both the Duchenne Regulatory Science Consortium (D-RSC) and Critical Path to Therapeutics for the Ataxias (CPTA).Continue reading→

TUCSON, Ariz., June 22, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) collaborators in Europe. HTG has now signed EAP agreements with customers in both the US and Europe and continues to progress toward its planned third quarter 2021 commercial launch of its HTG Transcriptome Panel, designed to measure approximately 20,000 mRNA targets using the HTG EdgeSeq technology.Continue reading→

As the 17^th president of NAU, José Luis Cruz Rivera has spent time talking with faculty, staff, students and community members, working with university leaders to plan for the fall semester and officially introducing himself and discussing his vision for the university.Continue reading→

For the third consecutive year, ASU is in the top 10 for U.S. patents issued to U.S. universities — and 11th worldwide — according to an annual ranking of the top universities by the National Academy of Inventors and the Intellectual Property Owners Association.Continue reading→

The CSBI-TEConomy Life Science Workforce Trends Report reflects Continued Resilience Amidst a Global Pandemic, Adjusting to Remote Work, and Advancing a More Diverse and Inclusive Industry. The report debuted at BIO Digital on June 17, 2021. 

Continue reading→

Continue reading→

PHOENIX, June 8, 2021 /PRNewswire/ — bioSyntagma^®, Inc unveiled the world’s first high-plex multi-omic spatial workflow designed for clinical samples and diagnostic applications.  Compatible with FFPE and large resections up to an inch in size, the Molecular Fingerprint™ (mPrint) technology has been demonstrated to map tumor microenvironments with custom PCR panels, targeted and total sequencing, and spatial imaging at resolutions ranging from single-cell to complex regions of interest.  bioSyntagma’s solution is the first to provide a pathway to diagnostic applications with its proprietary spatial-diagnostic machine learning engine that classifies tissues based on tumor microenvironment.  Continue reading→

• Phase 0 trial in ARDS subjects estimated completion by end of 1^st QTR 2022
• FDA indicates general agreement on required IND-enabling program for ALT-100 mAb in ARDS patients
• ALT-100 humanized mAb manufacturing initiated and speeding toward GMP completion

Continue reading→

TUCSON, Ariz., June 14, 2021 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed product design lock for the HTG Transcriptome Panel and announced three Early Adopter Program (EAP) collaborators. HTG continues to progress in its development of a planned transcriptome panel using the HTG EdgeSeq technology. This panel, expected to be called the HTG Transcriptome Panel, will measure approximately 20,000 mRNA targets, with a planned research use only commercial launch in the third quarter of 2021.Continue reading→

TUCSON, Ariz. – June 14, 2021 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company announced today that it has completed a Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). Avery received FDA feedback on its planned manufacturing and IND-enabling studies for its novel therapeutic candidate, MyCardia™, which is in development for the treatment of ischemic heart failure.Continue reading→